Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

• Published in: Epilepsia (Copenhagen) Vol. 60; no. 2; pp. 294 - 302
• Main Authors: Devinsky, Orrin, Nabbout, Rima, Miller, Ian, Laux, Linda, Zolnowska, Marta, Wright, Stephen, Roberts, Claire
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2019; John Wiley and Sons Inc
• Subjects: Adolescent; Adult; Anticonvulsants - therapeutic use; Appetite loss; Cannabidiol - therapeutic use; cannabinoid; Cannabinoids; Child; Child, Preschool; Clinical trials; Convulsions & seizures; Diarrhea; Double-Blind Method; Double-blind studies; Drug Therapy, Combination - methods; Epilepsies, Myoclonic - complications; Epilepsies, Myoclonic - drug therapy; epileptic encephalopathy; Female; Fever; Full‐length Original Research; Humans; Liver; Long-Term Care; Male; Middle Aged; Patients; Seizures; Seizures - etiology; Time; Transaminase; Treatment Outcome; treatment‐resistant epilepsy; Valproic acid; Valproic Acid - therapeutic use; Young Adult; seizures; treatment-resistant epilepsy; cannabinoid; epileptic encephalopathy

Summary Objective Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B (NCT02091375). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or a second placebo‐controlled trial,...